ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1138

Suppressor of Cytokine Signaling 1 Inhibits Interleukin-1β Induced Matrix Metalloproteinases Expression in Human Chondrocytes By Modulating p38-CREB- C/Ebpβ Pathway

You Jung Ha1, Yong Seok Choi2, Eun Ha Kang3, Kichul Shin4, Jaehyung Hur1, Yeong Wook Song5 and Yun Jong Lee2, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 2Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 4Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: chondrocytes, matrix metalloproteinase (MMP) and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: CAAT/enhancer-binding
protein-beta (C/EBPb) is known to be a transcription factor regulating IL-1b-induced
catabolic pathways, including the expression of matrix metalloproteinases
(MMPs), in chondrocytes. Suppressor of cytokine signaling 1 (SOCS1) was
reported to inhibit interleukin (IL)-1b signaling in chondrocytes. However, the
effect of SOCS1 on C/EBPb has not been explored.

Methods: To investigate the
interaction between SOCS1 and C/EBPb, we established human chondrocyte-like
SW1353 cell lines with overexpression or knockdown of SOCS1 or C/EBPb. MMP-1,
MMP-3, MMP-13, and C/EBPb transcripts were measured by using quantitative
real-time PCR. The expression of C/EBPb and cAMP response element-binding
protein (CREB) protein was evaluated by immunoblot. To evaluate the binding of
C/EBPb to MMP-13 promoter, chromatin immunoprecipitation (ChIP) assay was
performed.

Results: Both SOCS1 and C/EBPb
were involved in transcription of MMP-3 and MMP-13. When SW1353 cells were stimulated
with IL-1b, C/EBPb levels were significantly increased by SOCS1 knockdown and
decreased by SOCS1 overexpression (Fig. 1). Also, the same change in IL-1b induced
C/EBPb expression was observed in SOCS1 transfected human articular
chondrocytes (Fig. 1). But, C/EBPb overexpression or knockdown did not change
the levels of IL-1b-inducible SOCS1 (Fig. 1). SOCS1 did not affect the
ubiquitination of C/EBPb, but it regulated the levels of C/EBPb mRNA and
suppressed the phosphorylation of CREB1, an active transcription factor of C/EBPb
(Fig. 2). In addition, p38 MAPK, a target of SOCS1, was involved in the
phosphorylation of CREB1. The ChIP assay confirmed that SOCS1 overexpression resulted
in reduced binding of C/EBPb to MMP-13 promoter.

Conclusion: These results demonstrate
that SOCS1 down-regulates p38-CREB-C/EBPb pathway resulting in suppression of MMPs
expression in chondrocytes.

Fig.
1. SOCS1
knockdown increased and SOCS1 overexpression decreased IL-1b induced C/EBPb
mRNA and protein expression in SW1353 cells (a, c), but C/EBPb knockdown or
overexpression showed no alteration in SOCS1 transcript levels (b). In SOCS1-overexpressed
human articular chondrocytes, IL-1b-induced C/EBPb mRNA and protein expression showed
the same trends (d).

Fig.
2. Effects
of SOCS1 on phosphor-CREB levels in SW1353 cells.


Disclosure: Y. J. Ha, None; Y. S. Choi, None; E. H. Kang, None; K. Shin, None; J. Hur, None; Y. W. Song, None; Y. J. Lee, None.

To cite this abstract in AMA style:

Ha YJ, Choi YS, Kang EH, Shin K, Hur J, Song YW, Lee YJ. Suppressor of Cytokine Signaling 1 Inhibits Interleukin-1β Induced Matrix Metalloproteinases Expression in Human Chondrocytes By Modulating p38-CREB- C/Ebpβ Pathway [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/suppressor-of-cytokine-signaling-1-inhibits-interleukin-1-induced-matrix-metalloproteinases-expression-in-human-chondrocytes-by-modulating-p38-creb-cebp-pathway/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppressor-of-cytokine-signaling-1-inhibits-interleukin-1-induced-matrix-metalloproteinases-expression-in-human-chondrocytes-by-modulating-p38-creb-cebp-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology